KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amneal Pharmaceuticals (AMRX) Other Non-Current Liabilities: 2017-2024

Historic Other Non-Current Liabilities for Amneal Pharmaceuticals (AMRX) over the last 8 years, with Dec 2024 value amounting to $50.9 million.

  • Amneal Pharmaceuticals' Other Non-Current Liabilities rose 24.59% to $32.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $32.6 million, marking a year-over-year increase of 24.59%. This contributed to the annual value of $50.9 million for FY2024, which is 71.50% up from last year.
  • According to the latest figures from FY2024, Amneal Pharmaceuticals' Other Non-Current Liabilities is $50.9 million, which was up 71.50% from $29.7 million recorded in FY2023.
  • Amneal Pharmaceuticals' 5-year Other Non-Current Liabilities high stood at $87.5 million for FY2022, and its period low was $29.7 million during FY2023.
  • For the 3-year period, Amneal Pharmaceuticals' Other Non-Current Liabilities averaged around $56.0 million, with its median value being $50.9 million (2024).
  • Its Other Non-Current Liabilities has fluctuated over the past 5 years, first skyrocketed by 124.84% in 2022, then slumped by 66.07% in 2023.
  • Amneal Pharmaceuticals' Other Non-Current Liabilities (Yearly) stood at $83.4 million in 2020, then crashed by 53.33% to $38.9 million in 2021, then surged by 124.84% to $87.5 million in 2022, then tumbled by 66.07% to $29.7 million in 2023, then spiked by 71.50% to $50.9 million in 2024.